Description
Features and Benefits Blocks the production of prostaglandins by inhibiting cyclooxygenase （prostaglandin H synthase）, with greater selectivity toward the COX-1 isoform. The antithrombotic effect is due to the inhibition of COX-1 in plaets that blocks thromboxane production and plaet aggregation. Chemopreventive against colorectal and other solid tumors.

Properties
assay ≥99.0%
form crystalline
color white
pKa （25 °C） 3.5
mp 134-136 °C（lit.）
solubility H2O: 10 mg/mL at 37 °C
  H2O: 3 mg/mL at 25 °C
  ethanol: 50 mg/mL
  aqueous base: decomposes
abs. ε1mM/230 nm, aqueous acid 466
  ε1mM/231 nm, aqueous base 409
  ε1mM/278 nm, aqueous acid 68
  ε1mM/298 nm, aqueous base 190
Gene Information human ... ITGA2B（3674）, ITGB3（3690）, PTGS1（5742）, PTGS2（5743）

Safety
Personal Protective Equipment dust mask type N95 （US）, Eyeshields, Faceshields, Gloves
Hazard Codes Xn
Risk Statements 22-36/37/38
Safety Statements 26
WGK Germany 1
RTECS VO0700000
Flash Point（F） 482 °F
Flash Point（C） 250 °C

References
reference Gilroy, D. W., Differential effects of inhibition of isoforms of cyclooxygenase （COX-1 and COX-2） in chronic inflammation. Inflamm. Res. 47, 79, （1998）
  Gilroy, D. W., et al., Differential effects of inhibitors of cyclooxygenase （COX-1 and COX-2） in acute inflammation. Eur. J. Pharmacol. 355, 211-217, （1998）
  Schror, K., Aspirin and plaets: the antiplaet action of aspirin and its role in thrombosis treatment and prophylaxis. Semin. Thromb. Hemost. 23, 349-356, （1997）
  Shiff, S.J., et al., Cyclooxygenase inhibitors: drugs for cancer prevention. Curr. Opin. Pharmacol. 3, 352-361, （2003）
Merck Merck 13,856
Beilstein Beil. 10,IV,138
  Aldrich MSDS 1, 26:B / Corp MSDS 1 （1）, 48:C / FT-IR 1 （2）, 315:D / FT-IR 2 （2）, 2887:B / FT-NMR 1 （2）, 1293:B / IR-Spectra （2）, 909:F / IR-Spectra （3）, 1040:A / NMR-Reference 2 （2）, 303:D / RegBook 1 （2）, 1929:K / Sax 6, 88 / Sigma FT-IR 1 （1）, 610:B / Structure Index 1, 310:C:4

 Printable Reviews
Product ReviewsReview This Product